Silence Therapeutics PLC Significant Expansion of Intellectual Property (1978F)
May 16 2017 - 2:00AM
UK Regulatory
TIDMSLN
RNS Number : 1978F
Silence Therapeutics PLC
16 May 2017
Significant expansion of Intellectual Property (March to May
2017)
16 May 2017
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery, and development of novel RNA
therapeutics for the treatment of serious diseases with unmet
medical need, announces a significant expansion of its chemical
modification patent estate.
As previously announced in March 2017, the European Patent
Office granted patent EP 2258847B. This granted patent provides
Silence with further protection for its innovative chemical
modification technology across many European countries. We believe
this patented technology is relevant to third party medicines in
ongoing clinical trials for conditions including, but not
exclusively limited to, Hypercholesterolemia, TTR-mediated
Amyloidosis, Haemophilia and Acute Hepatic Porphyrias.
Subsequently, in May 2017, Silence has expanded and strengthened
its above patent estate by filing additional divisional and
continuation patent applications in Europe and the US respectively.
We believe these applications are also relevant to the third-party
medicines listed above. Chemical modification technology is vital
to prevent the degradation of therapeutic short interfering RNA
(siRNA) molecules and to enable potent RNA interference (RNAi). The
use of such technology has a substantial impact on the performance
of RNAi based drugs.
Silence may consider granting licences under its intellectual
property (IP). Previously, Quark Pharmaceuticals was granted a
royalty and milestone licence under the same patent estate for
certain products currently in Phase II and Phase III, which are
partnered with Novartis. Importantly, the licence to Quark was
granted at a pre-clinical stage in 2005, whereas the medicines for
the above listed conditions are in late-stage clinical
development.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics,
commented:
"These granted patents and patent applications within the US and
Europe are key to our leading IP position in the RNAi field and
build upon the pivotal nature of Silence's innovation, enabling our
core drug development business. In addition, we believe that
several third party late-stage clinical RNAi candidates, including
lipid nanoparticle and GalNAc based products, require licences
under our patent portfolio. The first launch for these medicines is
anticipated in 2018. We consider that potential licences under our
patent estate could have a significant financial effect relative to
the current market capitalisation of Silence."
Enquiries:
Silence Therapeutics plc Tel: +44 (0)20
Ali Mortazavi, Chief Executive 3457 6900
Officer
David Ellam, Chief Financial Officer
Canaccord Genuity Limited (Nominated Tel: +44 (0)20
Adviser and Joint Broker) 7523 8350
Henry Fitzgerald-O'Connor/Emma
Gabriel
Peel Hunt LLP (Joint Broker) Tel: +44 (0)20
James Steel/Oliver Jackson 7418 8900
Media Enquiries: Tel: +44 (0)
FTI Consulting 20 3727 1000
Simon Conway/Brett Pollard/Stephanie
Cuthbert
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics develops a new generation of medicines by
harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDBRGDUSBBBGRU
(END) Dow Jones Newswires
May 16, 2017 02:00 ET (06:00 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024